Followers | 17 |
Posts | 1755 |
Boards Moderated | 0 |
Alias Born | 11/13/2013 |
Sunday, October 13, 2019 9:22:16 AM
The following was posted on Stocktwits by Antihydrogen. Sorry, wasn't sure how to deal with the links in his file.
Antihydrogen's Notes on the Medical Research
Collaborative, LLC
Last updated: 20191012
Part of making any prudent investment is understanding the market, the product, and the people that run the company. The opposite is also true. We need to understand who's attacking a company, to understand their merit, and to understand their agenda to assess the sum of risks. One of my investment is in Amarin Corporation. Naturally I perform due diligence on fundamentals, leadership, and science. Today my focus is
on this entity called MRC (or Medical Research Collaborative, LLC) because their name keeps popping up in forums and places attempting to sway opinions from the shadows. The way they operate feels like a penny stock broiler room. In the past year alone MRC had been launching an incessant discrediting campaign (i.e. link, link, link, link, link) on Amarin Corporation. It's clear after reading their twitter feed (link) that this entity's goal is to manufacture short narratives for the purpose of making short trades and to sell research materials to support its short theses from its website (link). Good shorts stand behind their reputation. George Soros, Carl Icahn, and even Andrew Left of the infamous Citron Research. Who runs MRC and what are their reputations? I could be wrong, but I'm not often wrong, that this organization carries the attributes of an illegal stock manipulation enterprise. Let me take you on a short journey to learn about this so called self-designated reputable organization.
1. Medical Research Collaborative, LLC
What's in a name? Looking up any news about them leads to one paid Accesswire advertisement (link) announcing the launch of their website offering market research. Under the contacts list shows:
James Murphy
Executive Director of Marketing
Medical Research Collaborative, LLC
Phone: 1-877-427-1317
Email: admin@medicalresearchcollaborative.com
Web: https://medicalresearchcollaborative.com/
Source: https://medicalresearchcollaborative.com/
2. https://medicalresearchcollaborative.com/about_us
Let's visit MRC's official business website. However, it's also anonymous with no public representative shown. The contact page at least provides what appears to be a physical business address to a suite and
phone number (link).
Medical Research Collaborative
7901 4th St N STE 4081
St Petersburg
FL 33702
Telephone
1-(877)-427-1317
3. People work for you, right?
Searching LinkedIn pulled up only 2 names.
Steven Giardino (link)
President and CEO at Medical Research Collaborative, LLC
Tampa/St. Petersburg, Florida Area
James Murphy (link)
Executive Director Of Marketing at Medical Research Collaborative, LLC
Houston, Texas Area
Steven Giardino's profile matches the same area where MRC is located. What's James Murphy doing in Texas away from the company. In either case both the CEO and the Executive Director of Marketing have empty profiles. I expected to see a list of related prior work experiences on a site like on LinkedIn with a nice collection of industry connections.
After all this is how many industry professionals use LinkedIn to keep in touch these days.
4. At least you're a registered business, right?
According to the State of Florida's business registry MRC doesn't exist (link). According to the Texas Comptroller of Public Accounts MRC doesn't exist either (link). Surely the company must exist in a national business directory of 28m registered companies as an LLC right? MRC still doesn't (link). Medical Research Corporation, LLC doesn't exist.
5. Let's locate Steven Giardino, CEO, from Florida
No public records of Steven Giardino (link), nor Steve Giardino (link), nor Stephen Giardino (link) of Florida. Not on Been Verified either (link). Not on TruthFinder (link). This supposedly reputable CEO who personally writes Citizen Petitions to the FDA is a ghost. Eversept Partners (link, link) (Amarin is currently their 2nd largest holding) and King & Spalding (link) have also tried the FOIA route (link) and must have also reached the same conclusion.
6. Let's take a closer look at the office location
"7901 4th St N STE 4081" at first looks legitimate but upon digging into its owner, Bay West Center, something goes awry (link). There are only 3 office floors and every floor's suite only has 3 digits and the first
digit represents each floor. Where is suite 4081 located, on the roof?
It turns out the suite 4's (link) are actually mailboxes forwarded to a company called
NORTHWEST REGISTERED AGENT LLC (link)
7901 4TH ST N STE 300
ST. PETERSBURG, FL 33702
and this agent provides quick and dirty anonymous company registration services online. This is convenient for entities to disappear after gorging on enough money.
Wrapping up
In our short journey to learn who the reputable people supporting MRC were, we instead learned that nobody exists and neither does the company. Perhaps trusting sources that aren't willing to openly put their own reputation on the line should be treated with great suspicion. Everyone has an agenda. It's your job as it's mine to weed out seemingly true false data because that's a risk we can't afford to take with high stakes investments.
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM